Increased PON lactonase activity in morbidly obese patients is associated with impaired lipid profile

Ho-Plágaro, Ailec; García‐Serrano, Sara; Santiago‐Fernández, Concepción; Rodríguez‐Pacheco, Francisca; Garrido‐Sánchez, Lourdes; Rodriguez, Cristina; Valdés, Sergio; Gonzalo, Montserrat; Moreno-Ruiz, Francisco J.; Rodríguez‐Cañete, Alberto; Montiel-Casado, Custodia; Garcı́a-Fuentes, Eduardo

doi:10.1111/ijcp.13315

Cited by 6 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such relationship was absent in patients with arterial hypertension. However, other authors noted correlations between PON1 activity and HDL-C, TG, or BMI in persons with cardiovascular risk factors [27], also with arterial hypertension [10,11,14,28]. In our study the positive correlation between PON1 and CRP was observed, especially in the group with newly diagnosed hypertension.…”

Section: Discussioncontrasting

confidence: 56%

Arylesterase activity of paraoxonase 1 in patients with primary hypertension

Baszczuk

Wysocka

Płóciniczak

et al. 2021

Postępy Higieny I Medycyny Doświadczalnej

View full text Add to dashboard Cite

Introduction Paraoxonase 1 is an enzyme associated with high-density lipoprotein fraction and is considered to present antioxidant activity. Objectives The aim of the study was to assess the arylesterase activity of paraoxonase 1 (PON1) in the serum of patients with hypertension, due to effect of therapy and before treatment. Patients and Methods. The study was conducted in 76 patients with primary hypertension and 28 volunteers for the control group. Hypertensive subjects were assigned to one of three groups: well controlled (n=25), poorly controlled (n=26), and newly diagnosed before therapy (n=25) hypertension. We evaluated metabolic parameters in all participants using routine laboratory methods, as well as arylesterase activity of PON1. Results The four study groups differed with arylesterase activity of PON1 and the highest levels were found in patients with well controlled hypertension and the lowest in newly diagnosed. All patients diagnosed with hypertension presented negative correlations between PON1 and systolic and diastolic blood pressure. Conclusions Effective treatment of hypertension could result in increased PON1 activity, despite unfavorable homocysteine concentrations in blood. Untreated hypertension might decrease activity of PON.

show abstract

Section: Discussioncontrasting

confidence: 56%

Arylesterase activity of paraoxonase 1 in patients with primary hypertension

Baszczuk

Wysocka

Płóciniczak

et al. 2021

Postępy Higieny I Medycyny Doświadczalnej

View full text Add to dashboard Cite

show abstract

“…Additionally, several studies by Bajnok et al [29][30][31] reported low PARX activity in obese adults. However, other studies found no alterations in ARE, PARX, and LAC in patients with different degrees of obesity [32,33].…”

Section: Discussionmentioning

confidence: 82%

Serum Arylesterase, Paraoxonase, and Lactonase Activities and Paraoxonase-1 Concentrations in Morbidly Obese Patients and Their Relationship with Non-Alcoholic Steatohepatitis

Castañé,

Jiménez-Franco,

Martínez-Navidad

et al. 2023

Antioxidants

View full text Add to dashboard Cite

Paraoxonase-1 (PON1) is an antioxidant enzyme associated with high-density lipoproteins (HDL). Reduced serum PON1 activity is found in diseases marked by oxidative stress and inflammation, but its role in obesity remains unclear. This study investigated PON1 activities and concentrations in morbidly obese individuals and explored the impacts of the genetic polymorphism PON1 rs662 and non-alcoholic fatty liver disease on enzymatic properties. We recruited 1349 morbidly obese patients undergoing bariatric surgery and 823 non-obese volunteers. PON1-related variables, including arylesterase, paraoxonase, and lactonase activities and PON1 concentrations, were examined. Our results showed that morbidly obese individuals exhibited higher PON1 concentrations but lower enzymatic activities than non-obese individuals. We observed inverse associations of arylesterase and paraoxonase activities with waist circumference (rho = −0.24, p < 0.001, and rho = −0.30, p < 0.001, respectively) and body mass index (rho = −0.15, p = 0.001, and rho = −0.23, p < 0.001), as well as direct associations of arylesterase, paraoxonase, and lactonase activities with HDL cholesterol (rho = 0.11, p = 0.005, rho = 0.20, p < 0.001, and rho = 0.20, p < 0.001). No significant differences were observed regarding metabolic syndrome, type 2 diabetes mellitus, hypertension, dyslipidemia, rs662 polymorphism allele frequencies, or the diagnosis of non-alcoholic steatohepatitis. Nevertheless, correlations were found between certain PON1-related variables, steatosis, and ballooning. In conclusion, changes in PON1-related variables in morbidly obese patients are dependent on the disease itself and HDL levels. The relationships between these variables and specific liver histological changes raise intriguing questions for consideration in future studies.

show abstract

“…Another factor that has been thoroughly studied in association with PON1 lactonase activity is body weight. Three articles reported on the association between body weight and DHC lactonase activity (Alaminos-Castillo et al, 2019 ; Bacchetti et al, 2019 ; Rupérez et al, 2013 ), Ferré et al ( 2013 ) investigated TBBL and Cervellati et al ( 2018 ) focused on TBL. Of these five articles, three of them found a significant correlation between PON1 lactonase activity and obesity (Alaminos-Castillo et al, 2019 ; Bacchetti et al, 2019 ; Ferré et al, 2013 ).…”

Section: Resultsmentioning

confidence: 99%

“…Alaminos-Castillo et al ( 2019 ) reported that DHC lactonase activity is significantly decreased in obese subjects compared with nonobese controls, and increases after surgery. Bacchetti et al ( 2019 ) grouped cases into two categories, overweight women and obese women, and detected that DHC lactonase activity is significantly decreased in each subsequent category compared with healthy individuals (Bacchetti et al, 2019 ).…”

Section: Resultsmentioning

confidence: 99%

A Multi-Omics Analysis of PON1 Lactonase Activity in Relation to Human Health and Disease

Petrič

Kunej

Bavec

2021

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

Paraoxonase 1 (PON1) enzyme has antioxidative properties and is present in mammalian blood and several other body fluids. In blood, PON1 is usually integrated into the high-density lipoprotein (HDL) cholesterol. PON1 is a highly versatile enzyme displaying diverse functions such as arylesterase, lactonase, and paraoxonase, among others. PON1 activities are usually investigated with artificial substrates, for example, dihydrocoumarin and thiobutyl butyrolactone for lactonase activity. The PON1 enzyme activities measured with different substrates tend to be falsely assumed as being equivalent in the literature, although there are poor or weak correlations among the PON1 enzyme activities with different substrates. In addition, and despite our knowledge of the factors influencing PON1 paraoxonase and arylesterase activities, there is little knowledge of PON1 lactonase activity variations and attendant mechanisms. This is important considering further that the lactonase activity is the native activity of PON1. We report here a multi-omics analysis of PON1 lactonase activity. The influence of genetic variations, particularly of single nucleotide polymorphisms and epigenetic, proteomic, and lipidomic variations on PON1 lactonase activity are reviewed. In addition, the influence of various environmental, clinical, and demographic variables on PON1 lactonase activity is discussed. Finally, we examine the associations between PON1 lactonase activity and health states and common complex diseases such as atherosclerosis, dementias, obesity, and diabetes. To the best of our knowledge, this is the first multi-omics analysis of PON1 lactonase activity with an eye to future applications in basic life sciences and translational medicine and the nuances of critically interpreting PON1 function with lactones as substrates.

show abstract

Increased PON lactonase activity in morbidly obese patients is associated with impaired lipid profile

Cited by 6 publications

References 40 publications

Arylesterase activity of paraoxonase 1 in patients with primary hypertension

Arylesterase activity of paraoxonase 1 in patients with primary hypertension

Serum Arylesterase, Paraoxonase, and Lactonase Activities and Paraoxonase-1 Concentrations in Morbidly Obese Patients and Their Relationship with Non-Alcoholic Steatohepatitis

A Multi-Omics Analysis of PON1 Lactonase Activity in Relation to Human Health and Disease

Contact Info

Product

Resources

About